NCT04843553View on ClinicalTrials.gov

Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

February 8, 2019

Study Completion Date

December 18, 2020

Conditions
Actinic Keratoses
Interventions
DRUG

Oral Nicotinamide

All Listed Sponsors
lead

Rhode Island Hospital

OTHER

NCT04843553 - Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter